Differential Expression of IQGAP1/2 in Hepatocellular Carcinoma and its Relationship with Clinical Outcomes

  • Xia, Fa-Da (Department of General Surgery, Xiangya Hospital, Central South University) ;
  • Wang, Zhuo-Lu (Department of General Surgery, Xiangya Hospital, Central South University) ;
  • Chen, Hong-Xi (Department of General Surgery, Xiangya Hospital, Central South University) ;
  • Huang, Yun (Department of General Surgery, Xiangya Hospital, Central South University) ;
  • Li, Jin-Dong (Department of General Surgery, Xiangya Hospital, Central South University) ;
  • Wang, Zhi-Ming (Department of General Surgery, Xiangya Hospital, Central South University) ;
  • Li, Xin-Ying (Department of General Surgery, Xiangya Hospital, Central South University)
  • Published : 2014.06.30


Purpose: To investigate IQGAP1 and IQGAP2 expression in hepatocellular carcinoma (HCC) and itsassociation with HCC clinicopathological characteristics and survival outcomes. Methods: IQGAP1 and IQGAP2 mRNA and protein were measured in HCC tissues, para-tumor tissues and normal tissues by RT-PCR and Western blotting. We further examined 150 HCC samples with adjacent para-tumor tissues and 11 normal specimens by immunohistochemistry to evaluate the correlation of IQGAP1 and IQGAP2 with clinicopathological features and prognosis. Results: IQGAP1 mRNA and protein were up-regulated while IQGAP2 mRNA and protein were down-regulated in human HCC tissues compared with para-tumor and normal liver tissues (p<0.05). IQGAP1 expression was higher in primary HCC (122/150, 81.3%) than matched adjacent tissues (30/150, 20%, p<0.001), whereas IQGAP2 was lower (31/150, 20.7% as compared to 112/150, 74.7%, P<0.001). Positive IQGAP1 expression correlated with larger tumor size (p=0.002), advanced TNM stage (p=0.002) and tumor differentiation (III and IV, p=0.034). Negative IQGAP2 expression was significantly associated with larger tumor size (p=0.009), multicentric tumor occurrence (p=0.01), advanced TNM stage (0.009) and tumor differentiation (III and IV, p=0.020). Survival analysis revealed that patients with either IQGAP1+ or IQGAP2-tumors had significantly reduced disease-free survival (p<0.001 and 0.006 respectively) and overall survival (p<0.001 for both). Multivariate analysis showed that IQGAP1/2 switch was an independent prognosis factor for disease-free survival (HR=2.824) and overall survival (HR=2.189). Conclusion: Positive IQGAP1 and negative IQGAP2 expression were closely correlated with tumor progression and could be used as adjunctive biomarkers to improve prognostication for HCC patients.


Supported by : National Natural Science Foundation (NSFC) of China


  1. White CD, Brown MD, Sacks DB (2009). IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. Febs Lett, 583, 1817-24.
  2. Walch A, Seidl S, Hermannstadter C, et al (2008). Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer. Mod Pathol, 21, 544-52.
  3. Wang JB, Sonn R, Tekletsadik YK, Samorodnitsky D, Osman MA (2009). IQGAP1 regulates cell proliferation through a novel CDC42-mTOR pathway. J Cell Sci, 122, 2024-33.
  4. Wang NY, Wang C, Li W, et al (2014). Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev, 15, 1539-44.
  5. White CD, Erdemir HH, Sacks DB (2012). IQGAP1 and its binding proteins control diverse biological functions. Cell Signal, 24, 826-34.
  6. White CD, Khurana H, Gnatenko DV, et al (2010). IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol, 10, 125.
  7. Xie Y, Yan J, Cutz JC, et al (2012). IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. Biochim Biophys Acta, 1822, 875-84.
  8. Yu XL (2014). Serum peroxiredoxin 3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pac J Cancer Prev, 15, 2979-86.
  9. McCallum SJ, Wu WJ, Cerione RA (1996). Identification of a putative effector for Cdc42Hs with high sequence similarity to the RasGAP-related protein IQGAP1 and a Cdc42Hs binding partner with similarity to IQGAP2. J Biol Chem, 271, 21732-7.
  10. Joyal JL, Annan RS, Ho YD, et al (1997). Calmodulin modulates the interaction between IQGAP1 and Cdc42. Identification of IQGAP1 by nanoelectrospray tandem mass spectrometry. J Biol Chem, 272, 15419-25.
  11. Luo R, Zhang M, Liu L, et al (2013). Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One, 8, e70511.
  12. Maluccio M, Covey A (2012). Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 62, 394-9.
  13. Nabeshima K, Shimao Y, Inoue T, Koono M (2002). Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett, 176, 101-9.
  14. Nishikawa H, Kimura T, Kita R, Osaki Y (2013). Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer, 4, 635-43.
  15. Schmidt VA (2012). Watch the GAP: emerging roles for IQ motif-containing GTPase-activating proteins IQGAPs in hepatocellular carcinoma. Int J Hepatol, 2012, 958673.
  16. Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF (2008). Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol, 28, 1489-502.
  17. Thomas M (2009). Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol, 44, 136-41.
  18. Van Hengel J, D'Hooge P, Hooghe B, et al (2008). Continuous cell injury promotes hepatic tumorigenesis in cdc42-deficient mouse liver. Gastroenterology, 134, 781-92.
  19. Gnatenko DV, Xu X, Zhu W, Schmidt VA (2013). Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One, 8, e71826.
  20. Dong PX, Jia N, Xu ZJ, et al (2008). Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro. J Exp Clin Cancer Res, 27, 77-84.
  21. Elliott SF, Allen G, Timson DJ (2012). Biochemical analysis of the interactions of IQGAP1 C-terminal domain with CDC42. World J Biol Chem, 3, 53-60.
  22. Eom DW, Kang GH, Han SH, et al (2011). Gastric micropapillary carcinoma: A distinct subtype with a significantly worse prognosis in TNM stages I and II. Am J Surg Pathol, 35, 84-91
  23. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.
  24. Grohmanova K, Schlaepfer D, Hess D, et al (2004). Phosphorylation of IQGAP1 modulates its binding to Cdc42, revealing a new type of rho-GTPase regulator. J Biol Chem, 279, 48495-504.
  25. Hart MJ, Callow MG, Souza B, Polakis P (1996). IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J, 15, 2997-3005.
  26. Jadeski L, Mataraza JM, Jeong HW, Li Z, Sacks DB (2008). IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem, 283, 1008-17.
  27. Jin SH, Akiyama Y, Fukamachi H, et al (2008). IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer, 122, 1040-6.
  28. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9.
  29. Bernards A (2003). GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta, 1603, 47-82.
  30. Breuhahn K, Longerich T, Schirmacher P (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 25, 3787-800.
  31. Briggs MW, Sacks DB (2003). IQGAP proteins are integral components of cytoskeletal regulation. Embo Rep, 4, 571-4.
  32. Brill S, Li S, Lyman CW, et al (1996). The Ras GTPase-activatingprotein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol, 16, 4869-78.
  33. Brown MD, Sacks DB (2006). IQGAP1 in cellular signaling: bridging the GAP. Trends Cell Biol, 16, 242-9.
  34. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
  35. Casteel DE, Turner S, Schwappacher R, et al (2012). Rho isoformspecific interaction with IQGAP1 promotes breast cancer cell proliferation and migration. J Biol Chem, 287, 38367-78.
  36. Chen F, Zhu HH, Zhou LF, et al (2010). IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation. Exp Mol Med, 42, 477-83.

Cited by

  1. KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma vol.16, pp.1, 2016,
  2. Golgi protein 73 and its diagnostic value in liver diseases pp.09607722, 2018,
  3. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma vol.5, pp.12, 2018,